Encorafenib
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | DRUG-ENCORAFENIB |
|---|---|
| Tipo | Fármaco |
| Alegais | BraftoviЕнкорафеніб |
| Estado | reviewed 2026-04-26 | pending_clinical_signoff |
| Doenças | DIS-CRC DIS-MELANOMA |
| Fontes | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Fatos sobre as drogas
| Classe | Inibidor do BRAF (oral, seletivo do V600) |
|---|---|
| Mecanismo | Selective ATP-competitive BRAF V600E/K kinase inhibitor. Longer target-residence time vs vemurafenib/dabrafenib → less paradoxical ERK activation in WT BRAF cells. In mCRC BRAF V600E + cetuximab (BEACON CRC) — first BRAF-targeted approval in CRC. |
| Dose típica | CRC BRAF V600E (BEACON): 300 mg PO daily (with cetuximab 400→250 mg/m² weekly). Melanoma (with binimetinib): 450 mg PO daily. |
| Ucrânia registada | Verdade |
| NSZU reembolsado | Falso |
| Ucrânia verificada pela última vez | 2026-04-27 |
Notas
BEACON CRC (Kopetz NEJM 2019, Lancet 2022 update): encorafenib + cetuximab vs irinotecan/FOLFIRI + cetuximab control — mOS 9.3 vs 5.9 mo in BRAF V600E mCRC 2L+. Triplet arm (enco + cetux + binimetinib) showed numerically higher ORR but no OS benefit vs doublet — doublet is the current standard. COLUMBUS (melanoma): encorafenib + binimetinib vs vemurafenib mPFS 14.9 vs 7.3 mo. Skin surveillance for new cutaneous SCC and primary melanoma mandatory throughout treatment (BRAFi class effect — derm exam q3 mo). Baseline + serial ECG (QTc), LFTs, derm + ophthalmologic exam. UA: registered for melanoma + CRC indications; НСЗУ does not reimburse — out-of-pocket. Dabrafenib+trametinib remains the reimbursed BRAFi+MEKi combo in UA melanoma practice.
Usado por
Esquema terapêutico
REG-ENCORAFENIB-BINIMETINIB-MELANOMA- Encorafenib + binimetinib (melanoma BRAF V600E/ K)REG-ENCORAFENIB-CETUXIMAB- Encorafenib + Cetuximab (BEACON CRC)